NCT02339922 2026-03-05
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Active not recruiting
Clinical Trials
28 trialsNCT03506373 2026-03-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT04463953 2026-02-11
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
NCT02619682 2026-01-08
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT05722405 2026-01-05
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Recruiting
NCT04009109 2025-12-18
Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT02461888 2025-12-17
MUKEight
University of Leeds
Phase 2 Completed
NCT03618537 2025-12-04
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02253316 2025-11-10
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT02420847 2025-11-10
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03763162 2025-10-24
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03590652 2025-10-21
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
University of California, San Diego
Phase 2 Terminated
NCT02412228 2025-10-15
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
Phase 2 Completed
NCT03731832 2025-09-30
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
GWT-TUD GmbH
Phase 2 Completed
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT04052880 2025-07-20
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
Icahn School of Medicine at Mount Sinai
Phase 2 Active not recruiting
NCT05451771 2025-07-08
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Phase 1/2 Recruiting
NCT02765854 2025-06-26
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
Phase 2 Completed
NCT03817320 2025-06-17
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Active not recruiting
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT04047797 2025-04-20
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04998786 2025-04-06
I2D IFM2021_03
Nantes University Hospital
Phase 2 Active not recruiting
NCT03376672 2025-04-03
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
Helsinki University Central Hospital
Phase 2 Active not recruiting